Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer

Cancer Treatment Reviews

Volumn 31, Issue 8, 2005, Pages 648-652

  Lamberti, Christof ^a   Sauerbruch, T ^a   Glasmacher, A ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARMOFUR; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LETHARGY; LIFE EXPECTANCY; META ANALYSIS; MICROSATELLITE INSTABILITY; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT SELECTION; PROTEIN EXPRESSION; RISK REDUCTION; SHORT SURVEY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

EID: 27944441255     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.09.009     Document Type: Note

References (16)

1. C.R. Boland F.A. Sinicrope D.E. Brenner J.M. Carethers Colorectal cancer prevention and treatment Gastroenterology 118 2000 S115-S128
2. C.G. Moertel T.R. Fleming J.S. Macdonald et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report Ann Intern Med 122 1995 321-326
3. M. Miwa M. Ura M. Nishida et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274-1281
4. J. Schuller J. Cassidy E. Dumont et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291-297
5. E. Van Cutsem C. Twelves J. Cassidy et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study J Clin Oncol 19 2001 4097-4106
6. C. Twelves A. Wong M. Nowacki et al. Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696-2704
7. E. Poplin J. Benedetti N. Estes et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer J Clin Oncol 23 2005 1819-1825
8. J. Sakamoto Y. Ohashi C. Hamada et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials J Clin Oncol 22 2004 484-492
9. T. Andre C. Boni L. Mounedji-Boudiaf et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343-2351
10. N. Wolmark S. Wieand J.P. Kuebler L. Colangelo R.E. Smith A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07 (2005 ASCO Annual Meeting Proceedings) J Clin Oncol 23 2005 LBA3500
11. E. van Cutsem R. Labianca D. Hossfeld et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3) J Clin Oncol 23 2005 LBA8
12. H.J. Schmoll J. Tabernero M. Nowacki J. Maroun A. Figer T. Price et al. Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer (2005 ASCO Annual Meeting Proceedings) J Clin Oncol 23 2005 3523
13. H. Hurwitz L. Fehrenbacher W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335-2342
14. D. Cunningham Y. Humblet S. Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337-345
15. S. Popat R. Hubner R. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609-618
16. G. Peters C. Smorenburg C. Van Groeningen Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach J Chemother 16 Suppl. 4 2004 25-30